BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ramezani A, Baesi K, Banifazl M, Mohraz M, Khorvash F, Yaran M, Tabarsi P, Dalirrooyfard AH, Motevalli F, Bavand A, Aghakhani A. Naturally occurring NS5A and NS5B resistant associated substitutions in HCV and HCV/HIV patients in iranian population. Clin Res Hepatol Gastroenterol 2019;43:594-602. [PMID: 31080115 DOI: 10.1016/j.clinre.2019.01.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
Number Citing Articles
1 Ngwaga T, Kong L, Lin D, Schoborg C, Taylor LE, Mayer KH, Klein RS, Celentano DD, Sobel JD, Jamieson DJ, King CC, Tavis JE, Blackard JT. Diversity of the hepatitis C virus NS5B gene during HIV co-infection. PLoS One 2020;15:e0237162. [PMID: 32750098 DOI: 10.1371/journal.pone.0237162] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Gupta E, Agarwal R, Rastogi A, Rani N, Jindal A. Naturally Occurring Resistance Associated Substitutions in Non-Cirrhotic, Treatment Naive HCV-HIV Co-Infected Patients Does Not Affect the Treatment Response for Anti-HCV Antiviral Therapy. Infect Drug Resist 2021;14:1381-7. [PMID: 33880042 DOI: 10.2147/IDR.S301032] [Reference Citation Analysis]
3 Hasanshahi Z, Hashempour A, Ghasabi F, Moayedi J, Musavi Z, Dehghani B, Sharafi H, Joulaei H. First report on molecular docking analysis and drug resistance substitutions to approved HCV NS5A and NS5B inhibitors amongst Iranian patients. BMC Gastroenterol 2021;21:443. [PMID: 34819046 DOI: 10.1186/s12876-021-01988-y] [Reference Citation Analysis]